Literature DB >> 20514279

Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.

Wassim Kassouf1, Ashish M Kamat, Alexander Zlotta, Bernard H Bochner, Ronald Moore, Alan So, Jonathan Izawa, Ricardo A Rendon, Louis Lacombe, Armen G Aprikian.   

Abstract

Entities:  

Year:  2010        PMID： 20514279      PMCID： PMC2874590          DOI： 10.5489/cuaj.10051

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  71 in total

Review 1.  High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.

Authors:  Richard J Sylvester; Adrian van der Meijden; J A Witjes; Gerhard Jakse; Norio Nonomura; Chris Cheng; Aaron Torres; Roger Watson; Karl Heinz Kurth
Journal:  Urology       Date:  2005-12       Impact factor: 2.649

2.  Clinical model of lifetime cost of treating bladder cancer and associated complications.

Authors:  Elenir B C Avritscher; Catherine D Cooksley; H Barton Grossman; Anita L Sabichi; Lois Hamblin; Colin P Dinney; Linda S Elting
Journal:  Urology       Date:  2006-09-18       Impact factor: 2.649

3.  Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.

Authors:  Marco Racioppi; Angelo Porreca; Nazario Foschi; Giampaolo Delicato; Antonio Destito; Alessandro D'Addessi
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

4.  Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.

Authors:  J L Au; R A Badalament; M G Wientjes; D C Young; J A Warner; P L Venema; D L Pollifrone; J D Harbrecht; J L Chin; S P Lerner; B J Miles
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 13.506

5.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Authors:  D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

6.  Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response.

Authors:  T T Bui; P F Schellhammer
Journal:  Urology       Date:  1997-05       Impact factor: 2.649

7.  Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.

Authors:  A Losa; R Hurle; A Lembo
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

8.  The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.

Authors:  S Holmäng; H Hedelin; C Anderström; S L Johansson
Journal:  J Urol       Date:  1995-06       Impact factor: 7.450

9.  Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.

Authors:  Atsushi Takenaka; Yuji Yamada; Hideaki Miyake; Isao Hara; Masato Fujisawa
Journal:  Int J Urol       Date:  2008-04       Impact factor: 3.369

10.  Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule.

Authors:  M D Melekos; H Chionis; A Pantazakos; E Fokaefs; G Paranychianakis; H Dauaher
Journal:  J Urol       Date:  1993-04       Impact factor: 7.450
View more
  19 in total

1.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

Review 2.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

3.  iNOS expression and NO production contribute to the direct effects of BCG on urothelial carcinoma cell biology.

Authors:  Gopitkumar Shah; Guangjian Zhang; Fanghong Chen; Yanli Cao; Balaraman Kalyanaraman; William A See
Journal:  Urol Oncol       Date:  2013-09-17       Impact factor: 3.498

4.  Recurrence and upstaging rates of T1 high-grade urothelial carcinoma of the bladder on repeat resection in a Canadian, resource-limited, healthcare system.

Authors:  Adam Kinnaird; Peter Dromparis; Howard Evans
Journal:  Can Urol Assoc J       Date:  2018-04-06       Impact factor: 1.862

5.  Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study.

Authors:  Michael D Bell; Faysal A Yafi; Fadi Brimo; Jordan Steinberg; Armen G Aprikian; Simon Tanguay; Wassim Kassouf
Journal:  World J Urol       Date:  2016-02-23       Impact factor: 4.226

6.  Les nouvelles du Réseau canadien du cancer de la vessie.

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

7.  Highlights from the canadian bladder cancer network.

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

8.  The Canadian Bladder Cancer Network: efforts to improve patient care.

Authors:  Peter Black
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

9.  Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer.

Authors:  Faysal A Yafi; Armen G Aprikian; Joseph L Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; Fred Saad; David Bell; Darrel Drachenberg; Wassim Kassouf
Journal:  World J Urol       Date:  2013-11-10       Impact factor: 4.226

10.  The management of BCG failure in non-muscle-invasive bladder cancer: an update.

Authors:  Alexandre R Zlotta; Neil E Fleshner; Michael A Jewett
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.